期刊文献+

AML_1-ETO阳性的儿童急性髓系白血病疗效分析 被引量:7

Analysis of clinical outcome of childhood acute myeloid leukemia with AML_1-ETO
下载PDF
导出
摘要 目的探讨儿童急性髓系白血病m2型伴AML1-ETO阳性患儿的疗效及预后相关因素。方法2003年1月至2008年12月收住AML1-ETO阳性儿童m233例,并对患儿进行总结分析、随访。了解患儿临床特征,免疫分型,染色体核型治疗及疗效,生存情况及影响治疗的因素。结果33例AML1-ETO阳性儿童第一疗程诱导缓解率为63.5%,中位随访时间32个月,目前仍处于CR状态25例占75.5%,5例患儿骨髓复发,复发率为15.1%,高白细胞数,多脏器受累,免疫表型CD5+6以及第一疗程诱导治疗未达缓解者预后不良,并伴有较低的生存率。结论儿童急性髓系白血病M2伴有AML1-ETO阳性患儿预后是好的。强烈化疗高剂量阿糖胞苷能帮助提高疗效。提高生存率。高白细胞计数,累及多脏器以及CD56标记阳性和初次诱导治疗的缓解不佳,影响总的生存率。 Objective To analyze the clinical and prognostic factors of childhood acute myeloid leukemia with AML1-ETO. Methods Thirty-three children with AML1-ETO were analyzed on clinical features, immunophenotype, chromosome karyotype, treatment outcome and survival rate from 2003 to 2008. Results The complete remission rate of patients was 63.6% after the first course of induction therapy. Twenty-five children maintained complete remission (75.5 % ) and 5 children had bone marrow relapse (15.1% ). The median follow-up time was 32 months. White blood cells 325 × 10^9/L, multiple 'organ involved, CD56 positive and non-remission in the first induction therapy indicated poor prognosis. Conclusion Childhood acute myeloid leukemia with AML1-ETO have better prognosis. High whiteblood-cell count, multiple organ involved, CD56 positive and non-remission in the first induction therapy influence overall survival rate. Application of high dose Ara-C in consolidation therapy can improve therapeutic efficacy and prolong survival rate.
出处 《中国小儿血液与肿瘤杂志》 CAS 2010年第2期62-64,共3页 Journal of China Pediatric Blood and Cancer
关键词 儿童白血病 髓系M2 预后 Childhood leukemia AML1-ETO prognosis
  • 相关文献

参考文献9

  • 1Rowley TD,Ldentification of a translocation with quinacrine fluorescence in a patient with acnte leulcemia,1973,16:109-112.
  • 2Rowley ZD,Molecular qenetics in acute leukemia leukemia,2000,14:513-517.
  • 3王建祥,郝玉书,肖志坚,李建波,陈佩贞,卞寿庚,钱林生,孟庆祥.急性髓细胞白血病M_(2b)型AML_1-ETO融合基因转录本的检测[J].中华血液学杂志,1994,15(1):9-11. 被引量:12
  • 4Ferrare F,Vecchio LD.AwteMyeloid leukemia with t(8:21)/AML1-ETO:a distinct biological and cliaical entity,Haematologica.2002,87(3):306-319.
  • 5De J,Zan jani R,Hibbard M,et al.immunophenotypic profile predictive of KIT activating Mutations in AML1-ETO leulcemia.AM J clin pathol,2007,128(4):550-557.
  • 6Peterson LF,Yan M.Zhang DE,the p21 wall pathway is involved in blocking leukemogenesis by the t(8:21) fusion protein AMLIOETO.Blood,2007,109(10):4392-4398.
  • 7Hann IM,Webb DK.Gibson BE.et al.MRC trials in childhood acute Myeloid leukemia.Ann Hematol,2004,83(suppl 1):S 108-112.
  • 8Baer MR,stewart cc.lawrence D,et al.expression of the netral cell adhesion molemle CD56 is associated with short remission duration and surrival in acute myloid leukemia with t(8:21) (q22:q22).Blood,1997,90:1643-1650.
  • 9Bloomfield CD.shumac Regal L,et al.Long-termsurvival of patients with acute Myeloid.Cancer,1997,80:2191-2198.

二级参考文献2

  • 1卞寿庚,中华血液学杂志,1988年,9卷,10页
  • 2严文伟,中华内科杂志,1964年,12卷,714页

共引文献11

同被引文献81

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部